IP Library Granted Patent US 8,314,098
Granted Patent B2
US 8,314,098 · App. 13/169,958 · Granted Nov 20, 2012

Pyrazolo-pyrimidine compounds

Assignee: Ajinomoto Co., Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,314,098
App. No.
13/169,958
Granted
Nov 20, 2012
Kind
B2
Abstract

The present invention has searched for a variety of compounds which show IL-12/IL-23 production-inhibitory activities and herein provides a pharmaceutical composition and an agent for preventing or treating IL-12/IL-23 excess production-related diseases, which comprise the compound.

Claims (137)

1. A pyrazolo-pyrimidine compound represented by the following general formula (I), or a pharmaceutically acceptable salt thereof:

wherein m=0, 1, 2, 3, 4 or 5;

p=0 or 1;

U and V independently represent a single bond, O, S, S(O), S(O 2 ), NR a , C(O), C(O)O, C(O)NR a , OC(O), NR a C(O), NR a C(O)NR b , OC(O)NR a , NR a C(O)O, S(O)NR a , S(O 2 )NR a , NR a S(O), NR a S(O 2 ), CR 20 ═CR 21 , C≡C, or C═NR b ;

A is an aryl group, a heterocyclic group or an aliphatic ring group;

R 1 , R 18 and R 19 may be the same or different, and independently represent a hydrogen atom, a halogeno group, a hydroxyl group, an alkyl group which may have a substituent(s), a mercapto group, an alkoxy group which may have a substituent(s), an alkylthio group which may have a substituent(s), an alkylsulfonyl group which may have a substituent(s), an acyl group which may have a substituent(s), an acyloxy group which may have a substituent(s), an amino group which may have a substituent(s), a carboxyl group, an alkoxycarbonyl group which may have a substituent(s), a carbamoyl group which may have a substituent(s), a nitro group, a cyano group, a trifluoromethyl group, a sulfonic acid group, a sulfonamido group which may have a substituent(s), a sulfinamido group which may have a substituent(s), an aliphatic ring group which may have a substituent(s), an alkenyl group which may have a substituent(s), an alkynyl group which may have a substituent(s), a benzyloxy group which may have a substituent(s), an aryloxy group which may have a substituent(s), an aryl-vinyl group which may have a substituent(s), a hetero-aryloxy group which may have a substituent(s), an arylamino group which may have a substituent(s), a hetero-arylamino group which may have a substituent(s), an aryl-ethynyl group which may have a substituent(s), an aryl group which may have a substituent(s) or a heterocyclic group which may have a substituent(s);

R 2 and R 3 may be the same or different, and independently represent a hydrogen atom, a halogeno group, a hydroxyl group, an alkyl group which may have a substituent(s), a mercapto group, an alkoxy group which may have a substituent(s), an alkylthio group which may have a substituent(s), an alkylsulfonyl group which may have a substituent(s), an acyl group which may have a substituent(s), an acyloxy group which may have a substituent(s), an amino group which may have a substituent(s), a carboxyl group, an alkoxycarbonyl group which may have a substituent(s), a carbamoyl group which may have a substituent(s), a nitro group, a cyano group, a trifluoromethyl group, a sulfonic acid group, a sulfonamido group which may have a substituent(s), a sulfinamido group which may have a substituent(s), an aliphatic ring group which may have a substituent(s), an alkenyl group which may have a substituent(s), an alkynyl group which may have a substituent(s), a benzyloxy group which may have a substituent(s), an aryloxy group which may have a substituent(s), an aryl-vinyl group which may have a substituent(s), a hetero-aryloxy group which may have a substituent(s), an arylamino group which may have a substituent(s), a hetero-arylamino group which may have a substituent(s), an aryl-ethynyl group which may have a substituent(s), an aryl group which may have a substituent(s) or a heterocyclic group which may have a substituent(s);

R 20 and R 21 may be the same or different and independently represent a hydrogen atom, a halogeno group, an alkyl group which may have a substituent(s), an alkoxy group which may have a substituent(s), an alkylthio group which may have a substituent(s), an alkylsulfonyl group which may have a substituent(s), an acyl group which may have a substituent(s), an acyloxy group which may have a substituent(s), a carboxyl group, an alkoxycarbonyl group which may have a substituent(s), a carbamoyl group which may have a substituent(s), a nitro group, a cyano group, a trifluoromethyl group, a sulfonic acid group, a sulfonamido group which may have a substituent(s), a sulfinamido group which may have a substituent(s), an aliphatic ring group which may have a substituent(s), an alkenyl group which may have a substituent(s), an alkynyl group which may have a substituent(s), a benzyloxy group which may have a substituent(s), an aryloxy group which may have a substituent(s), an aryl-vinyl group which may have a substituent(s), a hetero-aryloxy group which may have a substituent(s), an arylamino group which may have a substituent(s), a hetero-arylamino group which may have a substituent(s), an aryl-ethynyl group which may have a substituent(s), an aryl group which may have a substituent(s) or a heterocyclic group which may have a substituent(s);

R 4 represents a hydrogen atom, a halogeno group, a hydroxyl group, a nitro group, a cyano group, an acyloxy group, a carboxyl group, a sulfonic acid group, a sulfonamido group which may have a substituent(s), a sulfinamido group which may have a substituent(s), an amino group which may have a substituent(s), an alkyl group which may have a substituent(s), an alkoxy group which may have a substituent(s), a mono- or di-alkylamino group which may have a substituent(s), an aryl group which may have a substituent(s), or a heterocyclic group which may have a substituent(s);

R 10 represents a hydrogen atom, an alkyl group which may have a substituent(s), an acyl group which may have a substituent(s), an alkylsulfonyl group which may have a substituent(s), an alkoxycarbonyl group which may have a substituent(s), a carbamoyl group which may have a substituent(s), an aryl group which may have a substituent(s), an aliphatic ring group which may have a substituent(s), or a heterocyclic group which may have a substituent(s);

R 14 represents NR c R d , an aliphatic ring group which may have a substituent(s), or a heterocyclic group which may have a substituent(s);

R 17 is a hydrogen atom;

G is a member selected from the group consisting of those represented by the following general formulas:

n=0, 1, 2, 3, 4 or 5;

q=0 or 1;

R 15 and R 24 may be the same or different and independently represent a hydrogen atom, an alkyl group which may have a substituent(s), an aliphatic ring group which may have a substituent(s), an aryl group which may have a substituent(s), or a heterocyclic group which may have a substituent(s);

R 5 and R 6 may be the same or different and independently represent a hydrogen atom, a halogeno group, a hydroxyl group, an alkyl group which may have a substituent(s), a mercapto group, an alkoxy group which may have a substituent(s), an alkylthio group which may have a substituent(s), an alkylsulfonyl group which may have a substituent(s), an acyl group which may have a substituent(s), an acyloxy group which may have a substituent(s), an amino group which may have a substituent(s), a carboxyl group, an alkoxycarbonyl group which may have a substituent(s), a carbamoyl group which may have a substituent(s), a nitro group, a cyano group, a trifluoromethyl group, a sulfonic acid group, a sulfonamido group which may have a substituent(s), a sulfinamido group which may have a substituent(s), an aliphatic ring group which may have a substituent(s), an alkenyl group which may have a substituent(s), an alkynyl group which may have a substituent(s), a benzyloxy group which may have a substituent(s), an aryloxy group which may have a substituent(s), an aryl-vinyl group which may have a substituent(s), a hetero-aryloxy group which may have a substituent(s), an arylamino group which may have a substituent(s), a hetero-arylamino group which may have a substituent(s), an aryl-ethynyl group which may have a substituent(s), an aryl group which may have a substituent(s), or a heterocyclic group which may have a substituent(s);

X represents a single bond, O, S, S(O), S(O 2 ), NR a , C(O), C(O)O, C(O)NR a , OC(O), NR a C(O), NR a C(O)NR b , OC(O)NR a , NR a C(O)O, S(O)NR a , S(O 2 )NR a , NR a S(O), NR a S(O 2 ), CR 20 ═CR 21 , C≡C, or C═NR b ;

E represents an aryl group, a heterocyclic group or an aliphatic ring group;

R 7 , R 22 and R 23 may be the same or different and independently represent a hydrogen atom, a halogeno group, a hydroxyl group, a boronyl group, an alkyl group which may have a substituent(s), a mercapto group, an alkoxy group which may have a substituent(s), an alkylthio group which may have a substituent(s), an alkylsulfonyl group which may have a substituent(s), an acyl group which may have a substituent(s), an acyloxy group which may have a substituent(s), an amino group which may have a substituent(s), a carboxyl group, an alkoxycarbonyl group which may have a substituent(s), a carbamoyl group which may have a substituent(s), a nitro group, a cyano group, a trifluoromethyl group, a sulfonic acid group, a sulfonamido group which may have a substituent(s), a sulfinamido group which may have a substituent(s), an aliphatic ring group which may have a substituent(s), an alkenyl group which may have a substituent(s), an alkynyl group which may have a substituent(s), a benzyloxy group which may have a substituent(s), an aryloxy group which may have a substituent(s), an aryl-vinyl group which may have a substituent(s), a hetero-aryloxy group which may have a substituent(s), an arylamino group which may have a substituent(s), a hetero-arylamino group which may have a substituent(s), an aryl-ethynyl group which may have a substituent(s), an aryl group which may have a substituent(s), or a heterocyclic group which may have a substituent(s);

R a and R b may be the same or different and independently represent a hydrogen atom, an alkyl group which may have a substituent(s), an alkoxy group which may have a substituent(s), an acyl group which may have a substituent(s), an alkylsulfonyl group which may have a substituent(s), an alkoxycarbonyl group which may have a substituent(s), carbamoyl group which may have a substituent(s), an aliphatic ring group which may have a substituent(s), an aryl group which may have a substituent(s), or a heterocyclic group which may have a substituent(s);

R 13 represents a hydrogen atom, an aryl group which may have a substituent(s), a heterocyclic group which may have a substituent(s) or an aliphatic ring group which may have a substituent(s);

R c and R d may be the same or different and independently represent an alkyl group which may have a substituent(s), an alkoxy group which may have a substituent(s), an acyl group which may have a substituent(s), an alkylsulfonyl group which may have a substituent(s), an alkoxycarbonyl group which may have a substituent(s), a carbamoyl group which may have a substituent(s), an aliphatic ring group which may have a substituent(s), an aryl group which may have a substituent(s) or a heterocyclic group which may have a substituent(s);

R e represents a hydrogen atom, an alkyl group which may have a substituent(s), an alkoxy group which may have a substituent(s), an acyl group which may have a substituent(s), an alkylsulfonyl group which may have a substituent(s), an alkoxycarbonyl group which may have a substituent(s), a carbamoyl group which may have a substituent(s), an aliphatic ring group which may have a substituent(s), an aryl group which may have a substituent(s) or a heterocyclic group which may have a substituent(s);

provided that each of the foregoing substituents may be one selected from the group consisting of halogeno groups, hydroxyl group, lower alkyl groups, mercapto groups, alkoxy groups, alkylthio groups, alkylsulfonyl groups, acyl groups, acyloxy groups, amino groups, alkylamino groups, carboxyl groups, alkoxycarbonyl groups, carbamoyl groups, nitro groups, cyano groups, trifluoromethyl group, aryl groups, and heterocyclic groups.

2. The compound or the pharmaceutically acceptable salt thereof as set forth in claim 1 , wherein, in the general formula (I),

G is a group represented by the foregoing general formula (II-1) or (II-2), wherein

R 7 , R 22 and R 23 may be the same or different and independently represent a hydrogen atom, a halogeno group, a hydroxyl group, an alkyl group which may have a substituent(s), a mercapto group, an alkoxy group which may have a substituent(s), an alkylthio group which may have a substituent(s), an alkylsulfonyl group which may have a substituent(s), an acyl group which may have a substituent(s), an acyloxy group which may have a substituent(s), an amino group which may have a substituent(s), a carboxyl group, an alkoxycarbonyl group which may have a substituent(s), a carbamoyl group which may have a substituent(s), a nitro group, a cyano group, a trifluoromethyl group, a sulfonic acid group, a sulfonamido group which may have a substituent(s), a sulfinamido group which may have a substituent(s), an aliphatic ring group which may have a substituent(s), an alkenyl group which may have a substituent(s), an alkynyl group which may have a substituent(s), a benzyloxy group which may have a substituent(s), an aryloxy group which may have a substituent(s), an aryl-vinyl group which may have a substituent(s), a hetero-aryloxy group which may have a substituent(s), an arylamino group which may have a substituent(s), a hetero-arylamino group which may have a substituent(s), an aryl-ethynyl group which may have a substituent(s), an aryl group which may have a substituent(s), or a heterocyclic group which may have a substituent(s).

3. The compound or the pharmaceutically acceptable salt thereof as set forth in claim 1 , wherein, in the general formula (I),

R 14 represents the following general formula:

wherein

r=0, 1 or 2;

s=0, 1 or 2;

t=0, 1, 2, 3 or 4;

t′=0, 1, 2, 3 or 4;

Z is N or CH;

W is O, S, S(O), S(O 2 ), NR g , C(O)NR g , CR 20 ═CR 21 , C≡C or NR g C(O);

R g is a hydrogen atom, a hydroxyl group, an alkyl group which may have a substituent(s), an alkoxy group which may have a substituent(s), an acyl group which may have a substituent(s), an alkoxycarbonyl group which may have a substituent(s), a carbamoyl group which may have a substituent(s), an aliphatic ring group which may have a substituent(s), an aryl group which may have a substituent(s), or a heterocyclic group which may have a substituent(s);

R 8 and R 8′ may be the same or different and each independently represent a hydrogen atom, a halogeno group, a hydroxyl group, an alkyl group which may have a substituent(s), a mercapto group, an alkoxy group which may have a substituent(s), an alkylthio group which may have a substituent(s), an alkylsulfonyl group which may have a substituent(s), an acyl group which may have a substituent(s), an acyloxy group which may have a substituent(s), an amino group which may have a substituent(s), a carboxyl group, an alkoxycarbonyl group which may have a substituent(s), a carbamoyl group which may have a substituent(s), a nitro group, a cyano group, a trifluoromethyl group, a sulfonic acid group, an aliphatic ring group which may have a substituent(s), an alkenyl group which may have a substituent(s), an alkynyl group which may have a substituent(s), a benzyloxy group which may have a substituent(s), an aryloxy group which may have a substituent(s), an arylvinyl group which may have a substituent(s), a hetero-aryloxy group which may have a substituent(s), an arylamino group which may have a substituent(s), a hetero-arylamino group which may have a substituent(s), an aryl-ethynyl group which may have a substituent(s), an aryl group which may have a substituent(s), or a heterocyclic group which may have a substituent(s); or alternatively R 8 and R 8′ may be bonded together to form an aryl group which may have a substituent(s), a 3- to 7-membered aliphatic ring ring which may have a substituent(s) or a 5- to 7-membered heterocyclic ring which may have a substituent(s); and

G is a group represented by the general formula (II-1).

4. The compound or the pharmaceutically acceptable salt thereof as set forth in claim 1 , wherein, in the general formula (I),

m is 0, 1 or 2;

n is 0, 1 or 2;

R 10 is a hydrogen atom;

U and V each independently represent a single bond, O, S, NR a , CR 20 ═CR 21 , C≡C, C(O)NR a , or NR a C(O);

X represents a single bond, O, S, NR a , C(O)O, C(O)NR a , OC(O), NR a C(O), CR 20 ═CR 21 , or C≡C;

Z is N;

r is 1;

s is 1; and

W is O, S, S(O), S(O 2 ) or NR g .

5. The compound or the pharmaceutically acceptable salt thereof as set forth in claim 1 , wherein, in the general formula (I),

G is a group represented by the general formula (II-1), wherein

n=0,

q=1, and

X represents a single bond.

6. The compound or the pharmaceutically acceptable salt thereof as set forth in claim 1 , wherein, in the general formula (I),

R 14 is a group represented by the general formula (III), wherein

Z is N,

W is O,

t=0, and

t′=0.

7. The compound or the pharmaceutically acceptable salt thereof as set forth in claim 1 , wherein, in the general formula (I),

p=1;

R 4 is a hydrogen atom;

G is a group represented by the general formula (II-1), wherein

n=0,

q=1, and

X represents a single bond; and

R 14 is a group represented by the general formula (III), wherein

Z is N,

W is O,

t=0, and

t′=0.

8. The compound or the pharmaceutically acceptable salt thereof as set forth in claim 1 , wherein the group represented by -(E(R 22 )(R 23 )) q —R 7 in the general formula (II-1) is a 6-indolyl group, an m-tolyl group or a 3-indolyl group.

9. The compound or the pharmaceutically acceptable salt thereof as set forth in claim 1 , wherein the group represented by -(E(R 22 )(R 23 )) q —R 7 in the general formula (II-1) is an m-tolyl group or a 3-indolyl group.

10. The compound or the pharmaceutically acceptable salt thereof as set forth in claim 7 , wherein, in the general formula (I),

p=1;

R 4 is a hydrogen atom;

m=0;

U is a single bond;

V is a single bond;

G is a group represented by the general formula (II-1), wherein

n=0,

q=1, and

X is a single bond; and

R 14 is a group represented by the general formula (III), wherein

Z is N;

W is O;

t=0; and

t′=0.

11. The compound or the pharmaceutically acceptable salt thereof as set forth in claim 10 , wherein the group represented by -(E(R 22 )(R 23 )) q —R 7 in the general formula (II-1) is a 6-indolyl group, an m-tolyl group or a 3-indolyl group.

12. The compound or the pharmaceutically acceptable salt thereof as set forth in claim 10 , wherein the group represented by -(E(R 22 )(R 23 )) q —R 7 in the general formula (II-1) is an m-tolyl group or a 3-indolyl group.

13. The compound or the pharmaceutically acceptable salt thereof as set forth in claim 1 , wherein

m=0, 1 or 2;

n=0, 1 or 2;

R 10 is a hydrogen atom; and

U and V each independently represent a single bond, O, S, S(O), S(O 2 ), C(O), C(O)O or OC(O).

14. The compound or the pharmaceutically acceptable salt thereof as set forth in claim 1 , wherein

G is a group represented by the general formula (II-1) or (II-2); and

X is a single bond, CR 20 ═CR 21 , or C≡C.

15. The compound or the pharmaceutically acceptable salt thereof as set forth in claim 1 , wherein, in the general formula (I),

R 14 is NR c R d or a group represented by the following general formula (III);

wherein r=0, 1 or 2;

s=0, 1 or 2;

t=0, 1, 2, 3 or 4;

t′=0, 1, 2, 3 or 4;

Z is N or CH;

W is O, S, S(O), S(O 2 ), NR g , CR g , C(O)NR g , CR 20 ═CR 21 , C≡C or NR g C(O);

R g is a hydrogen atom, a hydroxyl group, an alkyl group which may have a substituent(s), an alkoxy group which may have a substituent(s), an acyl group which may have a substituent(s), an alkoxycarbonyl group which may have a substituent(s), a carbamoyl group which may have a substituent(s), an aliphatic ring group which may have a substituent(s), an aryl group which may have a substituent(s), or a heterocyclic group which may have a substituent(s); and

R 8 and R 8′ may be the same or different and each independently represent a hydrogen atom, a halogeno group, a hydroxyl group, an alkyl group which may have a substituent(s), a mercapto group, an alkoxy group which may have a substituent(s), an alkylthio group which may have a substituent(s), an alkylsulfonyl group which may have a substituent(s), an acyl group which may have a substituent(s), an acyloxy group which may have a substituent(s), an amino group which may have a substituent(s), a carboxyl group, an alkoxycarbonyl group which may have a substituent(s), a carbamoyl group which may have a substituent(s), a nitro group, a cyano group, a trifluoromethyl group, a sulfonic acid group, an aliphatic ring group which may have a substituent(s), an alkenyl group which may have a substituent(s), an alkynyl group which may have a substituent(s), a benzyloxy group which may have a substituent(s), an aryloxy group which may have a substituent(s), an arylvinyl group which may have a substituent(s), a hetero-aryloxy group which may have a substituent(s), an arylamino group which may have a substituent(s), a hetero-arylamino group which may have a substituent(s), an aryl-ethynyl group which may have a substituent(s), an aryl group which may have a substituent(s), or a heterocyclic group which may have a substituent(s); or alternatively R 8 and R 8′ may be bonded together to form an aryl group which may have a substituent(s), a 3- to 7-membered aliphatic ring ring which may have a substituent(s) or a 5- to 7-membered heterocyclic ring which may have a substituent(s).

16. The compound or the pharmaceutically acceptable salt thereof as set forth in claim 1 , wherein, in the general formula (I),

R 14 is NR c R d or a group represented by the general formula (III);

Z is N;

t=0; and

t′=0.

17. A compound represented by the following general formula (IA), or a pharmaceutically acceptable salt thereof:

wherein m A =0, 1, or 2;

n A =0, 1, or 2;

R A1 and R A4 each independently represent a hydrogen atom, a halogeno group, a hydroxyl group, a nitro group, a sulfonic acid group, an amino group, an alkyl group which may have a substituent(s), an alkoxy group which may have a substituent(s), a mono- or di-alkylamino group which may have a substituent(s), a carbamoyl group which may have a substituent(s), or an aryl group which may have a substituent(s), a heteroaryl group which may have a substituent(s), or a heterocyclic group which may have a substituent(s);

R A2 , R A3 , R A5 and R A6 each independently represent a hydrogen atom, halogeno groups, a hydroxyl group, a nitro group, a sulfonic acid group, an amino group, an alkyl group which may have a substituent(s), an alkoxy group which may have a substituent(s), or mono- or di-alkylamino groups each of which may have a substituent(s);

R A7 represents an aryl group which may have a substituent(s), or a heteroaryl group which may have a substituent(s); and

R A8 and R A9 each independently represent an alkyl group which may have a substituent(s), or the group: NR A8 R A9 represents a cyclic amino group which may have a substituent(s).

18. The compound or the pharmaceutically acceptable salt thereof as set forth in claim 17 , wherein, in the general formula (IA),

R A1 and R A4 each independently represent a hydrogen atom, a halogeno group, a hydroxyl group, a nitro group, a sulfonic acid group, an amino group, an alkyl group which may have a substituent(s), an alkoxy group which may have a substituent(s), a mono- or di-alkylamino group which may have a substituent(s), or an aryl group which may have a substituent(s) or a heteroaryl group which may have a substituent(s).

19. The compound or the pharmaceutically acceptable salt thereof as set forth in claim 17 , wherein, in the general formula (IA),

m A is 0;

n A is 0;

R A1 and R A4 each independently represent a hydrogen atom, a halogeno group, or a member selected from the group consisting of phenyl groups and 5- or 6-membered monocyclic heteroaryl groups, which may be substituted with a substituent(s) selected from the group consisting of halogeno groups, alkyl groups having 1 to 3 carbon atoms, alkoxy groups having 1 to 3 carbon atoms, mono- or di-alkylamino groups each having 1 to 6 carbon atoms or a group represented by the following formula:

R A7 represents a group selected from the group consisting of phenyl groups, 5- or 6-membered monocyclic heteroaryl groups and fused bicyclic heteroaryl groups, each of which may be substituted with a substituent(s) selected from the group consisting of halogeno groups, alkyl groups each having 1 to 3 carbon atoms and alkoxy groups each having 1 to 3 carbon atoms; and

NR A8 R A9 is a 5- or 6-membered cyclic amino group.

20. The compound or the pharmaceutically acceptable salt thereof as set forth in claim 19 , wherein

R A1 represents a halogeno group, an alkyl group having 1 to 3 carbon atoms, an alkoxy group having 1 to 3 carbon atoms, a mono- or di-alkylamino group having 1 to 6 carbon atoms, or a member selected from the group consisting of phenyl groups and 5- or 6-membered heteroaryl groups, each of which may be substituted with a substituent(s) selected from the group consisting of those represented by the following formulas:

R A4 represents a hydrogen atom; and

NR A8 R A9 is a 4-morpholinyl group.

21. The compound or the pharmaceutically acceptable salt thereof as set forth in claim 17 , which is a compound represented by one of the following structural formulas:

22. The compound or the pharmaceutically acceptable salt thereof as set forth in claim 17 , which is a compound represented by one of the following structural formulas:

23. A pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt thereof as set forth in any one of claims 1 to 22 .

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 21, 2016
From: AJINOMOTO CO., INC.
To: EA PHARMA CO., LTD.
Reel/Frame 039094/0087 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 15, 2011
From: YAMAMOTO, TAKASHI; ANDOU, AYATOSHI; HAYAKAWA, NOBUHIKO; NOGUCHI, MASATSUGU; KURIBAYASHI, KANNA; EVIRYANTI, AGUNG; YOKOYAMA, RYOHEI; FUKUDA, SHUNSUKE; SUGIURA, TOSHIHIKO; KAGEYAMA, SHUNSUKE; SHIMA, YOICHIRO; NOGUCHI, MISATO
To: AJINOMOTO CO., INC.
Reel/Frame 026746/0900 →
Priority Claims (2)
JP 2008-334965 · Dec 26, 2008 · national
JP 2009-228755 · Sep 30, 2009 · national
Continuity (2)
Continuation PCTJP2009071786 · Dec 28, 2009
Related Publication 20110294781A1 · Dec 1, 2011